HERVolution Therapeutics Showcases Immuno-Oncology Research at European Lung Cancer Congress

According to a recent LinkedIn post from HERVolution Therapeutics, senior scientific leaders from the company are participating in the European Lung Cancer Congress 2026 in Copenhagen. The post notes that Senior Scientist María Pérez Penco, PhD, is presenting a poster on HERV-K as a shared tumor antigen in non–small cell lung cancer and its rationale for immunotherapy and checkpoint blockade combinations.

The company’s LinkedIn post highlights its active engagement with the European Society for Medical Oncology community and ongoing work in immuno-oncology. For investors, this type of scientific visibility may signal progress in validating the company’s research platform, potentially strengthening its credibility with partners, clinical collaborators, and future funding sources.

The focus on HERV-K as a shared tumor antigen in NSCLC suggests a strategy targeting broadly expressed cancer antigens, which could have implications for scalable therapeutic approaches. If the underlying science gains traction, it may position HERVolution Therapeutics more favorably within the competitive landscape of immunotherapies and combination regimens.

While the post does not reference clinical trial timelines, regulatory milestones, or commercial partnerships, presence at a major lung cancer congress often supports networking and potential business development discussions. Over time, such conference activity can contribute to a stronger pipeline narrative, which may be relevant for valuation assumptions in early-stage biotech investing.